Vaginal DHEA (Prasterone): What It Does, How It Compares, and Who Should Use It

What Exactly Is Vaginal DHEA and Why Does It Work?

Prasterone is dehydroepiandrosterone (DHEA) formulated as a soft vaginal suppository. Unlike oral DHEA supplements, which raise systemic sex-steroid levels unpredictably, the intravaginal route exploits a process called intracrinology: vaginal epithelial cells contain all the enzymatic machinery needed to convert DHEA locally into estradiol and testosterone, so the biological effect is concentrated in the tissue that needs it [1]. Systemic exposure stays low. Serum estradiol remains well within the normal postmenopausal range (<5 pg/mL change from baseline in key trials) [2].

Menopause drops circulating estrogen by roughly 90%, thinning the vaginal epithelium from 15-40 cell layers to fewer than 5, raising vaginal pH above 5.0, and reducing lubrication [3]. DHEA administered vaginally reverses those changes without requiring systemic estrogen therapy, which matters for women who have had estrogen-receptor-positive breast cancer or who simply prefer to avoid systemic hormones [4].

The FDA approved prasterone (Intrarosa, Endoceutics) in November 2016 specifically for moderate-to-severe dyspareunia associated with menopause [5]. The 2023 North American Menopause Society (NAMS) position statement on hormone therapy explicitly lists prasterone as a first-line option for genitourinary syndrome of menopause (GSM) [6].

The Clinical Trial Evidence Behind Prasterone

The approval rested on four phase-III randomized controlled trials. The best-powered was the AMKII study (N=422), a 52-week, double-blind, placebo-controlled trial in postmenopausal women with moderate-to-severe dyspareunia [7]. The four co-primary endpoints were: percentage of superficial cells on vaginal smear, percentage of parabasal cells, vaginal pH, and dyspareunia severity score.

At week 12, the 6.5 mg prasterone group showed [7]:

• Superficial cell percentage increased by 8.12 percentage points vs. 1.05 for placebo (P<0.001)
• Parabasal cell percentage decreased by 27.7 points vs. 3.4 for placebo (P<0.001)
• Vaginal pH dropped by 1.0 unit vs. 0.3 for placebo (P<0.001)
• Dyspareunia score fell by 1.42 points vs. 0.86 for placebo (P<0.001)

All four endpoints remained significant through 52 weeks [7]. Serum DHEA-S increased modestly, staying within the reference range for postmenopausal women, and serum estradiol did not rise above assay detection limits in most participants [2].

A secondary analysis of the same trial examined sexual function using the Female Sexual Function Index (FSFI). Women on prasterone showed statistically significant improvements in desire, arousal, lubrication, orgasm, satisfaction, and pain domains compared with placebo [8]. This finding is the basis for off-label discussion of prasterone for hypoactive sexual desire disorder (HSDD), although the FDA-approved indication remains specifically dyspareunia.

The safety profile across all four trials (combined N=over 1,200 women) was favorable. Vaginal discharge was the most common adverse effect, reported in approximately 8% of users vs. 3% placebo [5]. No cases of endometrial hyperplasia were observed in the 52-week arm, consistent with the local mechanism [7].

Vaginal DHEA vs. Vaginal Estradiol: Which One for GSM?

Both are FDA-approved, both work locally, and both relieve dyspareunia and dryness. The meaningful differences lie in mechanism, patient candidacy, and what they add beyond vaginal tissue health.

Vaginal estradiol products include Estrace cream (0.01% estradiol), Vagifem/Yuvafem tablets (10 mcg estradiol), and Estring ring (7.5 mcg/day over 90 days) [9]. They deliver estrogen directly. The vaginal epithelium responds, but there is no local testosterone component, so the androgen-mediated pathways that may contribute to clitoral sensitivity and desire are not addressed [10].

Prasterone generates both estradiol and testosterone inside vaginal cells [1]. That dual-hormone intracrine effect may explain the FSFI desire domain improvements seen in AMKII [8]. A 2021 network meta-analysis published in Menopause (N=over 8,000 women across 44 trials) found that vaginal estradiol and prasterone produced comparable improvements in vaginal pH and dyspareunia scores, but prasterone showed a numerically larger effect on sexual desire outcomes [11].

For women with estrogen-receptor-positive breast cancer currently on aromatase inhibitors, neither vaginal estradiol nor prasterone has been definitively cleared, but the 2023 NAMS statement notes that low-dose vaginal estradiol and prasterone are generally considered low-risk in this population when oncologist approval is obtained [6]. The Menopause Society and ASCO have both issued conditional endorsements for local therapy in this scenario [12].

Practically: if a patient's chief complaint is vaginal dryness and painful sex only, vaginal estradiol at the lowest effective dose is inexpensive and well-studied over decades. If she also reports reduced desire or arousal, prasterone's dual intracrine pathway gives it a plausible mechanism advantage [8].

Compounded Testosterone Cream for Women: A Separate Tool

Compounded testosterone cream for women is prescribed off-label in the United States because no FDA-approved female testosterone product exists domestically. Doses typically range from 0.5% to 2% cream applied to the clitoris, labia, or inner forearm, at 0.5-1 mL daily or several times weekly [13].

The evidence base is real but thinner than for prasterone. A 2019 Cochrane review (Davis SR et al., 46 trials, N=8,176) found that testosterone therapy in postmenopausal women produced statistically significant improvements in sexual function, including desire, arousal, and orgasm, with the largest effect sizes for HSDD [14]. The International Society for the Study of Women's Sexual Health (ISSWSH) 2019 process-of-care consensus statement recommends testosterone as a treatment option for postmenopausal HSDD after ruling out other causes [15].

The clinical distinction from prasterone is route and target tissue. Topical testosterone applied to genital skin acts systemically to some degree, and serum total testosterone can rise above the normal female range with higher doses or larger surface areas [13]. Monitoring serum testosterone is standard practice with compounded formulations. Prasterone, conversely, is designed to keep all hormonal action inside vaginal epithelial cells, with minimal serum spillover [1].

A useful prescribing decision framework used by the HealthRX medical team runs as follows. Start with the patient's primary complaint. Dyspareunia and dryness as the dominant symptom: offer prasterone or vaginal estradiol. HSDD without prominent vaginal symptoms: consider compounded testosterone cream or systemic options. Both symptom clusters present: prasterone addresses both pathways; alternatively, combine low-dose vaginal estradiol with compounded clitoral testosterone. Any approach requires baseline labs (total testosterone, free testosterone, SHBG, FSH, estradiol), symptom scoring with a validated tool such as the FSFI or PROMIS Sexual Function scales, and follow-up at 8-12 weeks.

Flibanserin (Addyi): The Centrally Acting Option for HSDD

Flibanserin (Addyi, Sprout Pharmaceuticals) is FDA-approved for premenopausal women with acquired, generalized HSDD [16]. It is a postsynaptic 5-HT1A agonist and 5-HT2A antagonist that also has dopamine D4 agonist activity, shifting the neurochemical balance in the prefrontal cortex toward sexual excitation [17].

The three phase-III BOUQUET trials (combined N=approximately 2,400 premenopausal women) demonstrated that 100 mg flibanserin nightly increased the number of satisfying sexual events (SSEs) by 0.5-1.0 events per month over placebo and reduced FSFI-desire subscale scores [18]. These are modest absolute numbers, and the FDA required a Risk Evaluation and Mitigation Strategy (REMS) due to hypotension and syncope risk when combined with alcohol or moderate-to-strong CYP3A4 inhibitors [16].

Flibanserin is not approved for postmenopausal HSDD, and it does not address vaginal atrophy at all. It is a purely central agent. Women on flibanserin must abstain from alcohol during use, which reduces real-world adherence [19]. For postmenopausal women with HSDD plus GSM, flibanserin is generally not the right first choice; prasterone or testosterone addresses the peripheral tissue changes that flibanserin ignores [15].

The NAMS 2022 consensus on female sexual dysfunction states: "Flibanserin is approved only for premenopausal HSDD and should not be used as a substitute for therapies addressing genitourinary atrophy" [20].

Bremelanotide (Vyleesi, PT-141): On-Demand Desire

Bremelanotide (Vyleesi, AMAG Pharmaceuticals) is an FDA-approved melanocortin receptor agonist administered as a 1.75 mg subcutaneous auto-injector 45 minutes before anticipated sexual activity [21]. It activates MC3R and MC4R receptors in the hypothalamus, increasing central sexual arousal independent of estrogen or testosterone levels [22].

The RECONNECT trials (two identical phase-III RCTs, combined N=1,247 premenopausal women with HSDD) showed bremelanotide increased SSEs by approximately 0.7 per month vs. placebo and reduced FSFI desire scores [23]. The most common adverse effects were nausea (40%), flushing (20%), and transient blood pressure elevation averaging 6 mmHg systolic for approximately 12 hours post-injection [21].

Unlike flibanserin, bremelanotide is on-demand rather than daily, which some patients prefer. Like flibanserin, it carries no approval for postmenopausal women and does nothing for vaginal tissue. The ISSWSH 2021 unmet needs paper notes bremelanotide has not been studied adequately in postmenopausal populations [24].

PT-141 is the peptide research name for the same compound. Compounded injectable PT-141 circulates widely in peptide clinics and telehealth platforms. The FDA has not approved any compounded version, and dosing consistency across compounding pharmacies varies. Patients considering PT-141 from a compounding pharmacy should verify the pharmacy holds a 503B outsourcing facility designation from the FDA [25].

Dosing, Administration, and Practical Use of Prasterone

The approved dose is one 6.5 mg suppository inserted vaginally each night at bedtime using the supplied applicator [5]. No dose titration is needed. Suppositories should be stored at room temperature, below 30°C (86°F). The onset of measurable tissue change (parabasal cell reduction, pH drop) begins within two weeks, but symptom relief for most patients takes four to eight weeks of consistent nightly use [7].

A compounded DHEA cream (typically 0.5% DHEA in a vaginal base) is available through 503A compounding pharmacies at lower cost than brand Intrarosa. The evidence base for compounded vaginal DHEA comes primarily from the same Endoceutics research team whose formulation became Intrarosa; bioavailability from cream vehicles may differ from suppository formulations, and direct comparative data are limited [26].

Patients using any vaginal product should be counseled that oil-based formulations degrade latex condoms. Prasterone suppositories contain a hydrogenated vegetable oil base, making them incompatible with latex [5]. Polyurethane or nitrile condoms are unaffected.

Monitoring and Follow-Up

Serum hormone levels do not require routine monitoring for brand prasterone because systemic absorption stays within normal postmenopausal ranges across the trial data [2]. Compounded DHEA or testosterone preparations deserve a different approach: check serum testosterone, DHEA-S, and estradiol at baseline and at 8-12 weeks after initiation, then every six months once stable [15].

Endometrial surveillance is not required for vaginal prasterone by current labeling, because systemic estradiol levels do not rise sufficiently to stimulate the endometrium [7]. Women with an intact uterus who also use systemic estrogen therapy do require progestogen protection regardless of what local vaginal therapy they use [6].

Who Should Not Use Prasterone

Current prescribing information lists no absolute contraindications beyond hypersensitivity to any product component [5]. The FDA label carries no warning against use in women with a history of breast cancer, which distinguishes prasterone from systemic estrogen products. Oncology societies, however, recommend discussing use with the treating oncologist before starting any hormone-adjacent therapy in women with active or recent hormone-sensitive cancers [12].

Prasterone is not indicated in premenopausal women, pregnant women, or children. No data support its use for HSDD in premenopausal patients, a gap that compounded testosterone cream and the centrally acting agents (flibanserin, bremelanotide) partially fill for that age group [16, 21].

Combining Therapies: When One Agent Is Not Enough

Some patients present with both GSM and HSDD. Treating the peripheral tissue problem (dryness, atrophy) often partially improves desire by removing the pain-avoidance cycle that suppresses libido. A 2022 analysis in the Journal of Sexual Medicine (N=289 postmenopausal women) found that 61% of women who achieved pain-free intercourse on vaginal therapy reported concurrent improvements in desire scores without any additional centrally acting treatment [27].

For patients where desire remains low after GSM resolution, adding compounded clitoral or labial testosterone cream to a prasterone regimen is a strategy used by sexual medicine specialists, though no large RCT has evaluated this combination directly [15]. Flibanserin and bremelanotide both carry FDA warnings against use without addressing contributing medical causes first, and GSM is explicitly listed as a treatable contributing cause [16, 21].

Cost, Coverage, and Access

Brand Intrarosa costs approximately $350-$450 per month without insurance as of early 2025. Some Medicare Part D plans and commercial insurers cover it under prior authorization when the diagnosis code N95.2 (atrophic vaginitis) or N94.1 (dyspareunia) is documented [5]. GoodRx and similar discount programs reduce cost to approximately $280-$320 at major pharmacy chains.

Compounded vaginal DHEA cream from a 503A pharmacy runs approximately $40-$80 per month. The trade-off is that bioavailability data are specific to the Intrarosa suppository formulation, and pharmacy-to-pharmacy variability in compounded products is real [26].

Compounded testosterone cream for women averages $60-$120 per month through telehealth platforms. Flibanserin (Addyi) listed at over $800 per month until generic versions entered the market in 2022, with generics now available for approximately $100-$150 per month [16]. Bremelanotide (Vyleesi) auto-injectors cost approximately $900 per kit (four injections), limiting use for many patients without adequate insurance coverage [21].